JP2016504311A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504311A5
JP2016504311A5 JP2015546770A JP2015546770A JP2016504311A5 JP 2016504311 A5 JP2016504311 A5 JP 2016504311A5 JP 2015546770 A JP2015546770 A JP 2015546770A JP 2015546770 A JP2015546770 A JP 2015546770A JP 2016504311 A5 JP2016504311 A5 JP 2016504311A5
Authority
JP
Japan
Prior art keywords
agent according
cells
stro
progeny
endothelial dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015546770A
Other languages
English (en)
Japanese (ja)
Other versions
JP6572130B2 (ja
JP2016504311A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2013/001452 external-priority patent/WO2014089623A1/en
Publication of JP2016504311A publication Critical patent/JP2016504311A/ja
Publication of JP2016504311A5 publication Critical patent/JP2016504311A5/ja
Application granted granted Critical
Publication of JP6572130B2 publication Critical patent/JP6572130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015546770A 2012-12-12 2013-12-12 内皮機能不全及び炎症の疾患の治療 Active JP6572130B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736361P 2012-12-12 2012-12-12
US61/736,361 2012-12-12
PCT/AU2013/001452 WO2014089623A1 (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019123243A Division JP6829288B2 (ja) 2012-12-12 2019-07-01 内皮機能不全及び炎症の疾患の治療

Publications (3)

Publication Number Publication Date
JP2016504311A JP2016504311A (ja) 2016-02-12
JP2016504311A5 true JP2016504311A5 (enExample) 2017-01-19
JP6572130B2 JP6572130B2 (ja) 2019-09-04

Family

ID=50933585

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015546770A Active JP6572130B2 (ja) 2012-12-12 2013-12-12 内皮機能不全及び炎症の疾患の治療
JP2019123243A Active JP6829288B2 (ja) 2012-12-12 2019-07-01 内皮機能不全及び炎症の疾患の治療
JP2021008250A Active JP7201715B2 (ja) 2012-12-12 2021-01-21 内皮機能不全及び炎症の疾患の治療
JP2022206042A Pending JP2023030116A (ja) 2012-12-12 2022-12-22 内皮機能不全及び炎症の疾患の治療
JP2024111736A Pending JP2024147655A (ja) 2012-12-12 2024-07-11 内皮機能不全及び炎症の疾患の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019123243A Active JP6829288B2 (ja) 2012-12-12 2019-07-01 内皮機能不全及び炎症の疾患の治療
JP2021008250A Active JP7201715B2 (ja) 2012-12-12 2021-01-21 内皮機能不全及び炎症の疾患の治療
JP2022206042A Pending JP2023030116A (ja) 2012-12-12 2022-12-22 内皮機能不全及び炎症の疾患の治療
JP2024111736A Pending JP2024147655A (ja) 2012-12-12 2024-07-11 内皮機能不全及び炎症の疾患の治療

Country Status (11)

Country Link
US (2) US20160175360A1 (enExample)
EP (2) EP3556850A1 (enExample)
JP (5) JP6572130B2 (enExample)
KR (3) KR102506612B1 (enExample)
CN (2) CN105358163B (enExample)
AU (4) AU2013360024B2 (enExample)
CA (1) CA2893942C (enExample)
ES (1) ES2742035T3 (enExample)
IL (1) IL239308A0 (enExample)
SG (2) SG10201705061RA (enExample)
WO (1) WO2014089623A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101828421B1 (ko) 2007-12-04 2018-02-12 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
KR102506612B1 (ko) * 2012-12-12 2023-03-06 메소블라스트, 아이엔씨. 내피 기능장애 및 염증 질환의 치료
JPWO2022114111A1 (enExample) * 2020-11-27 2022-06-02

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
EP1003501B9 (en) 1997-04-02 2005-06-08 The Brigham And Women's Hospital, Inc. Use of an agent for lowering the risk of cardiovascular disease
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US20080260694A1 (en) 2004-09-24 2008-10-23 Angioblast Systems, Inc. Multipotential Expanded Mesenchymal Precursor Cell Progeny (Memp) and Uses Thereof
KR101617319B1 (ko) 2005-04-12 2016-05-02 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체 세포의 분리
US20080241112A1 (en) 2005-05-10 2008-10-02 Christof Westenfelder Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
CA2743682A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
EP2227238A2 (en) * 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
KR101828421B1 (ko) * 2007-12-04 2018-02-12 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
KR102011609B1 (ko) * 2008-11-20 2019-08-16 메소블라스트, 아이엔씨. 췌장 기능장애를 치료 또는 예방하는 방법
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
WO2011073521A1 (en) * 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
WO2012047733A2 (en) * 2010-09-29 2012-04-12 Aidan Research And Consulting, Llc. Treatment of acne by conditioned media
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
CN109276706A (zh) * 2011-06-03 2019-01-29 麦瑟布莱斯特公司 治疗或预防神经性疾病的方法
WO2013003899A1 (en) * 2011-07-04 2013-01-10 Mesoblast, Inc Methods of treating or preventing rheumatic disease
AU2013296611B2 (en) * 2012-08-01 2017-11-23 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
KR102506612B1 (ko) * 2012-12-12 2023-03-06 메소블라스트, 아이엔씨. 내피 기능장애 및 염증 질환의 치료
EP2943069B1 (en) * 2013-01-09 2018-08-15 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Similar Documents

Publication Publication Date Title
Sinha et al. 5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach
Moreno et al. Pathophysiology of the cardiac late Na current and its potential as a drug target
JP2013523152A5 (enExample)
CL2013003331A1 (es) Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz.
JP2016517888A5 (enExample)
JP2014508138A5 (enExample)
JP2018505158A5 (enExample)
TN2017000270A1 (en) Use of prg4 as an anti-inflammatory agent
PH12018500261B1 (en) Azole benzene derivative
JP2009537554A5 (enExample)
JP2016511753A5 (enExample)
JP2016504311A5 (enExample)
JP2016502980A5 (enExample)
WO2010091051A3 (en) Therapeutic use of specialized endothelial progenitor cells
JP2014533256A5 (enExample)
PH12015502264A1 (en) Pyrazole derivative
JP2011527984A5 (enExample)
JP2018510917A5 (enExample)
You et al. Pathogenic and therapeutic roles of extracellular vesicles in sepsis
JP2016535762A5 (enExample)
JP2014506563A5 (enExample)
WO2021057061A1 (en) Senolytic and antiinflammatory prodrugs and methods of use thereof
JP2018509479A5 (enExample)
CN104398525B (zh) 闭花木酮的o-(哌嗪基)乙基衍生物在制备抗慢性阻塞性肺病药物中的应用
RU2018110607A (ru) Фармацевтическая композиция для предотвращения и лечения заболеваний печени, содержащая в качестве активного ингредиента кромолин или его фармацевтически приемлемую соль